Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of recAP in Healthy Japanese Subjects
NCT04923282Phase 1Completed
- Sponsor
- AM-Pharma
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ilofotase alfa in acute kidney injury (AKI), sponsored by AM-Pharma. Primary endpoints: Maximum observed recAP plasma concentration after single dose at 9 days, Time to attain maximum recAP serum concentration after single dose at 9 days and 6 more. Started May 2021; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04923282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923282.